AlphAIAlphAI — Financial news for AI agents
yahoo.comSEP 172 min read$CAH

How Is Cardinal Health's Stock Performance Compared to Other Health Care Services Stocks?

Cardinal Health (CAH) shares rose 1.3% after Q4 results showed adjusted EPS of $2.91, beating estimates, but revenue of $63.7B missed forecasts. The company expects full-year adjusted EPS of $12.40-$12.60. Analysts rate CAH a 'Strong Buy' with a mean price target of $270.88, implying 16.4% upside.

Original reporting
yahoo.com
Published Sep 17, 2026, 7:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 7:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
How Is Cardinal Health's Stock Performance Compared to Other Health Care Services Stocks? — source image
Source · yahoo.com
Decision brief

The 30-second read

$CAHBullishMed
01

Why it matters

The earnings beat and guidance lift sentiment, but revenue miss tempers enthusiasm.

02

Market read

Earnings release provides fresh data for traders targeting healthcare distribution stocks.

03

What to watch

Potential supply‑chain constraints and payer reimbursement trends.

Relevance 8/10Novelty 8/10Timing: post‑market Aug 11 release

Background

Cardinal Health is a major medical‑distribution company; earnings season influences sector sentiment.

Company-level read

Ticker impact

$CAHBullishHigh confidence
Context

Cardinal Health reported Q4 earnings with EPS beat and new full-year guidance.

Expected impact

stock may rise toward $270 target.

Evidence & confidence

Strong EPS beat and bullish analyst consensus indicate near-term price appreciation.

Market effects

Sector

Healthcare distribution sector may see renewed investor interest.

Regional

U.S. market participants focused on pharma distribution earnings.

Global

Limited to U.S. healthcare supply chain investors.

Counterpoint

What could challenge this read

Guidance still below expectations; revenue miss could pressure the stock.

Key entities

  • Company
    Cardinal Health

    U.S. medical‑distribution firm reporting Q4 results.

Read at source← All news

Related articles

SEP 11
$CAHHighAI 8/10

CAH Gains More Than 29% in 4 Months: Will the Uptrend Continue?

Cardinal Health (CAH) shares rose 29.3% over four months, driven by strong earnings from specialty businesses. Q4 2026 revenue increased 6% to $63.7B, with operating earnings up 30% to $935M. The company expects 3-5% pharma revenue growth in 2027 but 8-11% segment profit growth. Specialty business grew 25% in 2026, and acquisitions like Solaris are boosting growth. CAH trades at a forward P/E of 18.41X, above its 5-year median but below the S&P 500's 19.83X.

theglobeandmail.com2 min
SEP 3
$CAHHighAI 8/10

Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”

Jim Cramer highlighted Cardinal Health (CAH) as a favorite, citing its specialty pharmaceuticals and healthcare services growth. Q4 revenue rose 6% to $63.7B but missed estimates, while adjusted EPS was $2.91. Fiscal 2027 guidance includes non-GAAP EPS of $12.40-$12.60 and adjusted free cash flow of $3.5B-$4B. Risks include execution, drug pricing, and customer concentration.

insidermonkey.com3 min